Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Epitalon topic
No spam. Unsubscribe anytime.
Committee split on epitalon as FDA staff flag telomerase concerns; advocates cite decades of use
Summary
FDA staff concluded epitalon free base and acetate were not well characterized and raised a theoretical carcinogenicity concern tied to telomerase activation; several advisory members voted to add the substance to the 503A list citing long clinical use and monitored access.
The advisory committee debated epitalon's place on the 503A bulks list after hearing decades‑old literature, foreign clinical experience, and new public submissions.
FDA presenters said nominations used inconsistent naming and lacked critical impurity, aggregate, and endotoxin testing for injectable use. "The mechanism in which epitalon can upregulate telomerase and lengthen telomeres raise concerns that continuous exposure could enable cells to become cancerous," an FDA reviewer summarized during the safety section.
Supporters — including clinicians and some patient groups — urged the committee to favor a supervised access pathway rather than drive demand deeper underground. "Closing the regulated door doesn't close the demand and only removes the safest version of it," said Hani Sagari, founder and CEO of a longevity clinic, during public comment.
On the recorded advisory votes, the committee reported 7 yes, 4 no, and 1 abstention for both the free base and the acetate; members who voted yes cited clinical lineage, real‑world dispensing data provided to the committee, and the desire to replace unregulated online sources with pharmacy oversight. Those who voted no highlighted incomplete translation of foreign studies, missing characterization data, and the absence of human safety studies for the proposed subcutaneous route.
FDA staff said the committee's advice and new public docket comments will be considered as the agency proceeds with its evaluation for the proposed rule.
